Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A study looking at pazopanib for advanced kidney cancer (Pazo2)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This study looked at pazopanib for people with advanced kidney cancer (renal cancer) that hadn’t been treated yet.
This study was open to people whose cancer had spread to another part of the body and couldn’t have surgery to remove the cancer (advanced cancer).
This study was open for people to join between 2012 and 2016. These results were reported in 2018.
Cancer Research UK supported this study.
More about this trial
- if pazopanib helped people whose kidney cancer affected their well being and quality of life
- more about the side effects
Summary of results
- didn’t have serious side effects
- had stopped treatment for 3 weeks or more due to side effects
- were alive and had no sign of their kidney cancer
- 46 didn’t have serious side effects
- 18 had stopped treatment due to side effects
- 38 were alive and their cancer hadn’t started to grow again
How to join a clinical trial
Dr Emilio Porfiri
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Birmingham